Discontinued — last reported Q2 '24
Non-Current Assets
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)
Pfizer Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years) increased by 14.3% to $16.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 51.5%, from $33.00M to $16.00M.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ1 2021
Last reportedQ2 2024
Metric ID:
afs_debt_securities_fair_value_maturing_1_to_5yHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $86.00M | $454.00M | $598.00M | $406.00M | $381.00M | $371.00M | $293.00M | $249.00M | $168.00M | $101.00M | $33.00M | $26.00M | $14.00M | $16.00M |
| QoQ Change | — | +427.9% | +31.7% | -32.1% | -6.2% | -2.6% | -21.0% | -15.0% | -32.5% | -39.9% | -67.3% | -21.2% | -46.2% | +14.3% |
| YoY Change | — | — | — | +372.1% | -16.1% | -38.0% | -27.8% | -34.6% | -54.7% | -65.5% | -86.7% | -84.5% | -86.1% | -51.5% |
Range$14.00M – $598.00M
CAGR-40.4%
Avg YoY Growth-15.8%
Median YoY Growth-51.5%
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years) at Other Companies
Frequently Asked Questions
- What is Pfizer's available-for-sale debt securities - fair value (maturing 1 to 5 years)?
- Pfizer (PFE) reported available-for-sale debt securities - fair value (maturing 1 to 5 years) of $16.00M in Q3 2025.
- How has Pfizer's available-for-sale debt securities - fair value (maturing 1 to 5 years) changed year-over-year?
- Pfizer's available-for-sale debt securities - fair value (maturing 1 to 5 years) decreased by 51.5% year-over-year, from $33.00M to $16.00M.